Oncotarget

Oncotarget

LATEST COMMUNITY NEWS & EVENTS BY ONCOTARGET:

  • Behind the Study: Wnt Signaling Perturbs Spermatogenesis
    Dr. Pradeep Tanwar discusses his study published in Oncotarget in 2016, entitled, “Germ cell-specific sustained activation of Wnt signalling perturbs spermatogenesis in aged mice, possibly through non-coding RNAs.”
  • Behind the Study: Dendritic Cell Sarcoma & Rapid Research Autopsy
    Researchers from the Ohio State University describe their paper published by Oncotarget in 2019 titled, “Genomic characterization of metastatic ultra-hypermutated interdigitating dendritic cell sarcoma through rapid research autopsy.”
  • Behind the Study: Predictive miRNA Signature and Breast Cancer
    Researchers from the University of Vermont discuss their study published by Oncotarget in 2017 titled, “Development of a predictive miRNA signature for breast cancer risk among high-risk women.”

View All Posts >>

ABOUT ONCOTARGET.NET:

Read about community news and events sponsored by Oncotarget – a bi-weekly peer-reviewed open access scientific journal focusing on all topics surrounding cancer research. Visit Oncotarget.org for the latest articles about new and trending peer-reviewed scientific papers published by Oncotarget, part of the Impact Journals family of scientific publications.

ABOUT ONCOTARGET:

Oncotarget is published by Impact Journals of Orchard Park, New York. Impact Journals meets the standards established Wellcome Trust Publisher Requirements and is included on the Wellcome Trust List of Compliant Publishers.

Oncotarget is proud to have multiple Nobel Prize winning members on its editorial board, in addition to editors who have won the Lasker Prize and other prestigious recognitions. The open-access model employed by Oncotarget allows for free dissemination of thoroughly vetted peer-reviewed research material to the general public, leading to bigger and more frequent scientific breakthroughs. Because of Oncotarget’s uniquely varied scope, the journal has consistently published research on a wide range of subject areas, allowing readers to access an unparalleled diversity of knowledge in only one publication.

The founding editors of Oncotarget are Mikhail (Misha) Blagosklonny and Andrei Gudkov. Dr. Blagosklonny is well-known for his research in the field of aging, having published numerous papers on the subject. Mikhail is credited for advancing groundbreaking research of the drug Rapamycin, an anti-aging medicine that has shown to slow down the aging process. Having been featured in numerous publications on aging including a Scientific American article titled “A New Path to Longevity,” Mikhail continues to provide meaningfully important contributions to the scientific community.

CONTACT INFORMATION:

Dr. Blagosklonny can be followed on Twitter @Blagosklonny and you can visit his website here.

To get in touch with Oncotarget, please visit our website. The journal’s ISSN is 1949-2553 and is indexed and/or archived in PubMed, Scopus, PMC, and the Chan Zuckerberg Meta initiative.